APA (7th ed.) Citation

Swigris, J. J., Maher, T. M., Corte, T. J., Fischer, A., Xiao, H., Lancaster, L., . . . Charles, E. D. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Swigris, Jeffrey J., et al. Phase 2 Trial Design of BMS-986278, a Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist, in Patients with Idiopathic Pulmonary Fibrosis (IPF) or Progressive Fibrotic Interstitial Lung Disease (PF-ILD). BMJ Publishing Group.

MLA (9th ed.) Citation

Swigris, Jeffrey J., et al. Phase 2 Trial Design of BMS-986278, a Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist, in Patients with Idiopathic Pulmonary Fibrosis (IPF) or Progressive Fibrotic Interstitial Lung Disease (PF-ILD). BMJ Publishing Group.